Wolterk/iStock Editorial via Getty Images Beats on both lines in Medtronic's ( NYSE: MDT ) fiscal 2025 Q1 results prompted the medical device company to raise its EPS outlook and organic revenue growth for the year. The company now sees FY25 diluted non-GAAP EPS guidance of $5.42 to $5.
50, up from $5.40 to $5.50.
Also, organic revenue growth was upped to 4.5% to 5% from 4% to 5%. In Q1, Medtronic reported non-GAAP EPS of $1.
23, a $0.03 increase from the year-ago period. The company saw year-over-year revenue growth across all of its business units, except for medical surgical, which fell 0.
4%. Medtronic ended the quarter (July 26) with cash and cash equivalents of ~$1.31B compared to ~$1.
28B on April 26. More on Medtronic Medtronic plc 2025 Q1 - Results - Earnings Call Presentation Medtronic: Healthy Vital Signs Heading Into Earnings Medtronic: Still A Buy Before Earnings Medtronic Non-GAAP EPS of $1.23 beats by $0.
03, revenue of $8B beats by $100M Medtronic Q1 2025 Earnings Preview: Steady improvement in sales expected.
